Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 4/20 | 0.68 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | CASP7 | P55210 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.68 |
| ▸ | BLM | P54132 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.63 |
| ▸ | HTR1A | P08908 | 1/20 | 0.63 |
| ▸ | THPO | P40225 | 1/20 | 0.63 |
| ▸ | NMUR2 | Q9GZQ4 | 1/20 | 0.63 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.59 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30534867 | 1.00 | HIF1A (0.68) | HIF1AADRB2CYP2C9TSHRLMNA | |
| Hydrochloric Acid SCHEMBL6456085 | 0.98 | HIF1A (0.66) | HIF1AADRB2CYP2C9TSHRLMNA | |
| SCHEMBL2298032 | 0.83 | ADRB2 (0.56) | HIF1AADRB2CYP2C9TSHRLMNA | |
| SCHEMBL20687559 | 0.83 | ADRB2 (0.56) | HIF1AADRB2CYP2C9TSHRLMNA | |
| SCHEMBL2295573 | 0.83 | ADRB2 (0.56) | HIF1AADRB2CYP2C9TSHRLMNA | |
| SCHEMBL2293172 | 0.83 | ADRB2 (0.56) | HIF1AADRB2CYP2C9TSHRLMNA | |
| SCHEMBL2299015 | 0.83 | ADRB2 (0.56) | HIF1AADRB2CYP2C9TSHRLMNA | |
| SCHEMBL2294136 | 0.83 | ADRB2 (0.58) | HIF1AADRB2CYP2C9TSHRLMNA | |
| SCHEMBL10484862 | 0.83 | ADRB2 (0.56) | HIF1AADRB2CYP2C9TSHRLMNA | |
| SCHEMBL2295878 | 0.83 | ADRB2 (0.58) | HIF1AADRB2CYP2C9TSHRLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111721845-B | Synchronous detection method for five related substances of compound ipratropium bromide solution for inhalation | 鲁南制药集团股份有限公司 | 2023-08-15 | — | — | CN | claimed |
| CN-111721845-A | Synchronous detection method for five related substances of compound ipratropium bromide solution for inhalation | 鲁南制药集团股份有限公司 | 2020-09-29 | — | — | CN | claimed |
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-04-25 | — | — | US | claimed |
| EP-3426239-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2019-01-16 | — | — | EP | claimed |
| WO-2017153737-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2017-09-14 | — | — | WO | claimed |
| EP-4676481-A1 | COMBINATION OF BETA-2-ADRENERGIC RECEPTOR AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR USE IN TREATING HYPERGLYCAEMIA | Atrogi AB (SE) | 2026-01-14 | — | — | EP | disclosed |
| EP-4665321-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND METFORMIN FOR USE IN TREATING OBESITY AND REDUCING BODY FAT | Atrogi AB (SE) | 2025-12-24 | — | — | EP | disclosed |
| EP-4651867-A1 | BETA 2-ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OR PREVENTION OF MUSCLE WASTING | Atrogi AB (SE) | 2025-11-26 | — | — | EP | disclosed |
| WO-2024184408-A1 | COMBINATION OF BETA-2-ADRENERGIC RECEPTOR AGONISTS AND GLP-1 RECEPTOR AGONISTS FOR USE IN TREATING HYPERGLYCAEMIA | ATROGI AB (SE) | 2024-09-12 | — | — | WO | disclosed |
| WO-2024170727-A1 | COMBINATIONS OF BETA 2-ADRENERGIC RECEPTOR AGONISTS AND METFORMIN FOR USE IN TREATING OBESITY AND REDUCING BODY FAT | ATROGI AB (SE) | 2024-08-22 | — | — | WO | disclosed |
| WO-2024153813-A1 | BETA 2-ADRENERGIC RECEPTOR AGONISTS FOR TREATMENT OR PREVENTION OF MUSCLE WASTING | ATROGI AB (SE) | 2024-07-25 | — | — | WO | disclosed |
| CN-111721845-B | Synchronous detection method for five related substances of compound ipratropium bromide solution for inhalation | 鲁南制药集团股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2019-04-25 | — | — | US | disclosed |
| WO-2019053428-A1 | BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019053428-A1 | BETA-HYDROXYETHYLAMINES FOR USE IN THE TREATMENT OR PREVENTION OF NON-ALCOHOLIC FATTY LIVER DISEASES | ATROGI AB (SE) | 2019-03-21 | — | — | WO | disclosed |
| EP-3426239-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | Atrogi AB (SE) | 2019-01-16 | — | — | EP | disclosed |
| WO-2017153737-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2017-09-14 | — | — | WO | disclosed |
| WO-2017153737-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | ATROGI AB (SE) | 2017-09-14 | — | — | WO | disclosed |
| WO-2005108381-A1 | SYNTHESIS AND USES OF SYNEPHRINE DERIVATIVES | SYNTECH (SSPF) INTERNATIONAL INC. (US) | 2005-11-17 | — | — | WO | disclosed |
| US-20050250944-A1 | Synthesis and uses of synephrine derivatives | SYNTECH (SSPF) INTERNATIONAL INC. | 2005-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250944-A1 | Synthesis and uses of synephrine derivatives | ADRB3, ADRB2, ADRB1 | HIF1A 3823/4885ADRB2 2/4885CYP2C9 2074/4885 |
| US-20190119196-A1 | COMPOUNDS FOR THE TREATMENT OF HYPERGLYCAEMIA | SLC5A2, SLC5A1, SLC2A2 | HIF1A 527/4885ADRB2 229/4885CYP2C9 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.